NGL FINECHEM
|
|
BOM : 524774     NSE : NGLFINE     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Apr 19,2024 |
Price(EOD): ₹ 2,544.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,577.62 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NGL FINECHEM | 4.4% | -1.1% | 73.9% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
FUNDAMENTAL ANALYSIS OF NGL FINECHEM
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NGL FINECHEM
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
41
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 38.34 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] 7.06
P/B Calculated based on Book Value of Rs 222.55 Cr
[Latest Year - Mar2023 - Consolidated Results ] 5.02
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 313.06 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
348% 134% 146% |
SHARE PRICE MOMENTUM OF NGL FINECHEM
NGL FINECHEM vs SENSEX
DEBT OF NGL FINECHEM
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.14 0.15 0.11 0.13 |
0.15 0.15 0.11 0.14 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NGL FINECHEM
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NGL FINECHEM
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
9.7% -0.72% 2.82% -4.24% |
22.27% 41.32% 58.98% 54.7% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
NGL FINECHEM related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | -1.6% | 8.4% | 61.4% |
S&P BSE MIDSMALLCAP | -2.1% | 6.3% | 61.6% |
S&P BSE ALLCAP | -2.5% | 2.7% | 37.3% |
S&P BSE HEALTHCARE | -3.6% | 0.7% | 51.1% |
You may also like the below Video Courses
FAQ about NGL FINECHEM
Is NGL FINECHEM good for long term investment?
As on Apr 19,2024, the Fundamentals of NGL FINECHEM look Strong and hence it may be good for long term investment! See Financial Performance of NGL FINECHEM . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NGL FINECHEM UnderValued or OverValued?
As on Apr 19,2024, NGL FINECHEM is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NGL FINECHEM ?
As on Apr 19,2024, the Intrinsic Value of NGL FINECHEM is Rs. 1,033.93 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 567.85
Fair Value [Median EV / Sales Model] : Rs. 1,087.46
Fair Value [Median Price / Sales Model] : Rs. 1,033.93
Estimated Median Fair Value of NGL FINECHEM : Rs. 1,033.93
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.